BenevolentAI
investment highlights and technologically differentiated approach that has produced a rich portfolio of drug programmes proven computational engine scales cation and development of novel therapeutic candidates with higher probability of success versatile platform is disease and drug modality agnostic supported by deep experimental capabilities and for patient molecular mechanisms high value partnerships with and validate leadership and success of technology platform highly credible and experienced team with unique ability to combine traditional research practices with technology at all stages of drug discovery clinical trials and flexible business model with optionality to out license drug candidates at different stages of clinical development numerous near term value in proof points ulcerative colitis candidate selected in and phase i for atopic dermatitis in mid | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
40 of 42
Related slides by other companies
Evotec
Investor Day
November 2020
of all drugs fail in late stages of clinical development us billion only | Evotec
Genetron
Results
June 2022
in drug development services for i a | Genetron
Certara
Investor Day
December 2021
virtual drug development for a neglected tropical disease | Certara
Genetron
Results
August 2021
in drug development services for cay arm | Genetron
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io